🇺🇸 FDA
Patent

US 10167259

Allosteric inhibitors of proteasome and methods of use thereof

granted A61KA61K31/69A61K45/06

Quick answer

US patent 10167259 (Allosteric inhibitors of proteasome and methods of use thereof) held by The Board of Regents of the University of Texas System expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/69, A61K45/06